Tang Chao, Qi Jun, Wu Yan, Luo Ling, Wang Ying, Wu Yongzhong, Shi Xiaolong
Radiation and Cancer Biology Laboratory, Radiation Oncology Center, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing Cancer Hospital, Chongqing University Cancer Hospital and Chongqing Cancer Institution, Chongqing, China.
Front Genet. 2022 Nov 22;13:1069112. doi: 10.3389/fgene.2022.1069112. eCollection 2022.
Radiation therapy (RT) is one of the main treatments for cancer. The response to radiotherapy varies widely between individuals and some patients have poor response to RT treatment due to tumor radioresistance. Stratifying patients according to molecular signatures of individual tumor characteristics can improve clinical treatment. In here, we aimed to use clinical and genomic databases to develop miRNA signatures that can predict response to radiotherapy in various cancer types. We analyzed the miRNAs profiles using tumor samples treated with RT across eight types of human cancers from TCGA database. These samples were divided into response group (S, = 224) and progressive disease group (R, = 134) based on RT response of tumors. To enhance the discrimination for S and R samples, the predictive models based on binary logistic regression were developed to identify the best combinations of multiple miRNAs. The miRNAs differentially expressed between the groups S and R in each caner type were identified. Total 47 miRNAs were identified in eight cancer types ( values <0.05, t-test), including several miRNAs previously reported to be associated with radiotherapy sensitivity. Functional enrichment analysis revealed that epithelial-to-mesenchymal transition (EMT), stem cell, NF-κB signal, immune response, cell death, cell cycle, and DNA damage response and DNA damage repair processes were significantly enriched. The cancer-type-specific miRNA signatures were identified, which consist of 2-13 of miRNAs in each caner type. Receiver operating characteristic (ROC) analyses showed that the most of individual miRNAs were effective in distinguishing responsive and non-responsive patients (the area under the curve (AUC) ranging from 0.606 to 0.889). The patient stratification was further improved by applying the combinatorial model of miRNA expression (AUC ranging from 0.711 to 0.992). Also, five miRNAs that were significantly associated with overall survival were identified as prognostic miRNAs. These mRNA signatures could be used as potential biomarkers selecting patients who will benefit from radiotherapy. Our study identified a series of miRNA that were differentially expressed between RT good responders and poor responders, providing useful clues for further functional assays to demonstrate a possible regulatory role in radioresistance.
放射治疗(RT)是癌症的主要治疗方法之一。个体对放疗的反应差异很大,一些患者由于肿瘤的放射抗性而对RT治疗反应不佳。根据个体肿瘤特征的分子特征对患者进行分层可以改善临床治疗。在此,我们旨在利用临床和基因组数据库开发能够预测各种癌症类型对放疗反应的miRNA特征。我们使用来自TCGA数据库的八种人类癌症中接受RT治疗的肿瘤样本分析了miRNA谱。根据肿瘤的RT反应,这些样本被分为反应组(S,n = 224)和疾病进展组(R,n = 134)。为了增强对S和R样本的区分能力,基于二元逻辑回归开发了预测模型,以确定多个miRNA的最佳组合。确定了每种癌症类型中S组和R组之间差异表达的miRNA。在八种癌症类型中总共鉴定出47种miRNA(P值<0.05,t检验),包括一些先前报道与放疗敏感性相关的miRNA。功能富集分析表明,上皮-间质转化(EMT)、干细胞、NF-κB信号、免疫反应、细胞死亡、细胞周期以及DNA损伤反应和DNA损伤修复过程显著富集。鉴定出了癌症类型特异性的miRNA特征,每种癌症类型由2-13个miRNA组成。受试者工作特征(ROC)分析表明,大多数单个miRNA在区分反应性和无反应性患者方面是有效的(曲线下面积(AUC)范围为0.606至0.889)。通过应用miRNA表达的组合模型进一步改善了患者分层(AUC范围为0.711至0.992)。此外,鉴定出与总生存期显著相关的五种miRNA作为预后miRNA。这些mRNA特征可作为选择将从放疗中受益的患者的潜在生物标志物。我们的研究鉴定出一系列在RT反应良好者和反应不佳者之间差异表达的miRNA,为进一步的功能测定提供了有用的线索,以证明其在放射抗性中可能的调节作用。